In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.
Traci DeVito
Advertisement
Articles by Traci DeVito
Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.
The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.
Research presented this week at ESMO studied the efficacy of biosimilars to trastuzumab compared with the reference product in breast cancer.
Advertisement
Latest Updated Articles
Key Advances in Oncology, 2018January 17th 2019
Oncology Conference Highlights, Q4January 17th 2019
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
Achieving a “Functional Cure” With Multiple Myeloma Therapy
5